Biotech-academia deals, Leqembi’s latest data and what’s next for James Wilson: a BioCentury podcast

Small companies seeking pipeline solutions from academics far from biotech hubs. Standout Leqembi data. What’s next for Wilson after Penn

A substantial part of the biopharma ecosystem involves deals between biotechs and academics, with smaller companies accessing assets to add to their pipelines and technologies to help solve problems. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the interplay of biotech and academia, including how deals between the groups often come outside the hubs of Boston and the Bay Area and what types of indications and technologies are common focus points.

They also discuss new data in Alzheimer’s for Leqembi lecanemab from Eisai Co. Ltd. (Tokyo:4523) that provide insight into how to get the most out of anti-amyloid mAbs for the disease, and what’s next for James Wilson now that the gene therapy pioneer is moving on from the University of Pennsylvania. 

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.